This work presents an approach developed to circumvent uncertainties inherent in docking and scoring based on homology models. We combine docking and QSAR methods in a hybrid ligand- and homology structure-based design approach. This strategy enables us to come up with an alternative way of evaluating new compounds of a known series.
No takes yet. Share an insight, caveat, or question.
Sven Grüneberg (2005) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: